首页> 外文期刊>Medical Devices: Evidence and Research >In vitro study of RRS? Silisorg CE Class III medical device composed of silanol: effect on human skin fibroblasts and its clinical use
【24h】

In vitro study of RRS? Silisorg CE Class III medical device composed of silanol: effect on human skin fibroblasts and its clinical use

机译:RRS的体外研究? Silisorg CE III类由硅烷醇组成的医疗器械:对人皮肤成纤维细胞的作用及其临床用途

获取原文
           

摘要

Introduction: Silanol (organic silicon) has been used for decades in the treatment of skin photoaging as it stabilizes and maintains skin structures through hydrogen bonding electrostatic interaction with extracellular matrix (ECM) proteins or glycosaminoglycans. Organic silicon-based products are often presented as silanol derivatives which are currently associated to other structural molecules such as orthohydroxybenzoate, carboxymethyl theophylline alginate, ascorbate, acetyltyrosine, sodium lactate or mannuronate. Consequently, organic silicon formulations may differ substantially between the medical devices available on the market, which may result in additional effect on the skin. Therefore, there is a real need for a better characterization of the products in terms of their action on human skin and in vitro skin model. Materials and methods: In this in vitro study, the effect of RRS? Silisorg was analyzed. RRS? Silisorg is a dermal implant (CE Class III medical device) containing monomethylsilanol mannuronate associated to an antioxidant resveratrol. Skin fibroblast viability and capacity to induce the production of key ECM genes were evaluated in the presence of different concentrations of RRS? Silisorg. The key ECM genes selected were collagen type I, elastin and hyaluronan synthase type 2 (HAS2), which is the cellular enzyme responsible for high-molecular weight hyaluronic acid (HA) production. Viability was evaluated through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and expression was quantified by quantitative polymerase chain reaction. Results: RRS? Silisorg increased fibroblast gene expression of HAS2 in the first 24 hours, 25 times in the presence of 1 mg/mL of solution, followed by a collagen type I gene expression (4.7 times) and elastin expression (2.5 times) increase after 48 hours. Conclusion: These results demonstrate that the silanol-based medical device RRS? Silisorg sustains HA, collagen and elastin production in human skin fibroblasts in vitro.
机译:简介:硅烷醇(有机硅)已经用于治疗皮肤光老化,因为它通过与细胞外基质(ECM)蛋白或糖胺聚糖的氢键静电相互作用来稳定和维持皮肤结构。有机硅基产品通常以硅烷醇衍生物形式存在,目前与其他结构分子(如邻羟基苯甲酸酯,羧甲基茶碱藻酸盐,抗坏血酸盐,乙酰基酪氨酸,乳酸钠或甘露糖醛酸酯)相关。因此,市场上可买到的医疗设备之间的有机硅配方可能会大不相同,这可能会导致对皮肤的额外影响。因此,真正需要根据其对人皮肤和体外皮肤模型的作用来更好地表征产品。材料和方法:在这项体外研究中,RRS的作用是? Silisorg进行了分析。 RRS? Silisorg是一种皮肤植入物(CE III类医疗设备),含有与抗氧化剂白藜芦醇相关的单甲基硅烷醇甘露糖醛酸酯。在存在不同浓度的RRS?的情况下评估了皮肤成纤维细胞的活力和诱导关键ECM基因产生的能力。西里索格。选择的关键ECM基因为I型胶原蛋白,弹性蛋白和2型透明质酸合酶(HAS2),这是负责生产高分子量透明质酸(HA)的细胞酶。通过3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四溴化铵)测定法评估生存力,并通过定量聚合酶链反应定量表达。结果:RRS? Silisorg在最初的24小时内增加了HAS2的成纤维细胞基因表达,在1 mg / mL溶液存在的情况下增加了25倍,然后在48小时后I型胶原基因表达(4.7倍)和弹性蛋白表达(2.5倍)增加。结论:这些结果证明了基于硅烷醇的医疗器械RRS? Silisorg在人体皮肤成纤维细胞中维持HA,胶原蛋白和弹性蛋白的产生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号